What makes a CTO reply to outreach?

Evidence you understand their stack constraints and won't waste engineering time. Mention a real integration, a failure mode, or a security question you already answered. Demo theater is how you get routed to /dev/null. Name the stall they care about, offer one small next step, and stop before the thread feels like a sequence.

What subject line works for Pharmaceuticals cold email emails (long time no contact)?

Name the situation and the business object, not your excitement. Something like "Pharmaceuticals note on follow-up that ignores MLR, off-label risk," outperforms "Just checking in" because a CTO can decide from the preview text whether it's worth opening. Keep it under 50 characters when you can.

How many times should I follow up with a CTO (long time no contact)?

Don't follow a cold email the next morning. Give it 4 business days. Send when you have a real trigger: news, a useful artifact, a role change, a season. After that, send a breakup note and archive it. A CTO who wants it will answer a clean close more often than a fifth bump.

Should I mention a mutual connection in a cold email?

Only if the connection would be comfortable with it. Name-dropping someone who barely knows you can backfire. If you do mention them, say exactly how you know them in one clause and move on. Name the stall they care about, offer one small next step, and stop before the thread feels like a sequence.

Is it weird to email someone after six months of silence?

Not if you have a new reason and you don't pretend the old thread is still warm. Lead with the trigger, remind them who you are in one line, and make the ask optional. Nostalgia without news is just another cold email with extra steps.

Pharmaceuticals · CTO · Long Time No Contact

Cold Email for Pharmaceuticals CTO: Long Time No Contact

The query is practical: what should a cold email to a Pharmaceuticals CTO say for long time no contact? Start with a direct answer, add one proof point about follow-up that ignores MLR, off-label risk, and the fact that 'just a quick claim' isn't quick, and close with ask if the old problem still exists, or if you should leave

Last updated: 2026-09-02 · Reviewed by: Sales Email Template editors

We write templates the way we wrote emails on quota: short, specific, and easy to forward. When we cite research below, it is because the number changes how a buyer reads your note, not to pad the page.

Sources: HubSpot sales email benchmarks; Gong follow-up research

Why does this cold email work for a Pharmaceuticals CTO?

Give them permission to say you're early.
Speaks to follow-up that ignores MLR, off-label risk, and the fact that 'just a quick claim' isn't quick instead of a generic "value prop."
Fits how a CTO actually reads: 90 words is plenty if the substance is real. Don't pad.
Bring a new observation about their world, then offer a small, optional next step.
Make the first ask smaller than a 30-minute call.

When should I send this to a Pharmaceuticals CTO?

Don't follow a cold email the next morning. Give it 4 business days. Send when you have a real trigger: news, a useful artifact, a role change, a season. For this combo, treat "Only when you have a trigger" as the default, then adjust around launch calendars and review boards set speed. you don't. If you're emailing a CTO, 90 words is plenty if the substance is real. Don't pad.

What this CTO actually cares about

A CTO in Pharmaceuticals is protecting reliability, security, and engineering time. They look for architecture, failure modes, and whether you'll create toil for their team. Fluff is a ranking signal that you don't know the work. The hook that earns a look is an incident class, a security gap, or a cost line they already hate. The ask should stay at this size: a technical working session or a written teardown, not a 'vision call'. Delete trigger: Calling it 'AI-powered' with no description of the system. They look for architecture, failure modes, and whether you'll create toil for their team. Fluff is a ranking signal that you don't know the work.

How Pharmaceuticals changes the note

Pharmaceuticals buyers are commercial, medical, and ops leads who work under review boards and long timelines. Don't invent clinical claims. Don't treat HCPs like a funnel. If you don't know the rules, your email is a liability. A credible proof point in this vertical sounds like: cut review cycles on a leave-behind by catching claims issues before legal saw the tenth draft. Watch the language. Words that land here include MLR, label, access, HCP, congress, promotional review. Proof that lands: cut review cycles on a leave-behind by catching claims issues before legal saw the tenth draft.

How should I customize this template before I send it?

Replace the pain line with an agency waiting on MLR while the sales team keeps asking 'is it approved yet'.
Keep the tone precise.
Research one real trigger. Fake personalization is worse than none.
Time it for Only when you have a trigger. Send when you have a real trigger: news, a useful artifact, a role change, a season.
Don't use consumer-startup slang. It's a credibility leak.

What mistakes should I avoid with this long time no contact note?

Opening with your company story is how cold email dies.
Don't open with 'it's been a while' and then paste the old pitch.
Don't use consumer-startup slang. It's a credibility leak.
Calling it 'AI-powered' with no description of the system.

How does this long time no contact scenario compare?

Dimension	For this template
Best send window	Only when you have a trigger
Ideal length	90 words is plenty if the substance is real. Don't pad.
Primary ask	a technical working session or a written teardown, not a 'vision call'
Industry metric to cite	time through MLR, access, and compliant engagement rates
Tone	Precise. No slogans. It's fine to be a little dry.
Unlike no response	This isn't a 4-day bump. It's a re-introduction with a new reason.
Unlike breakup	You're opening a door, not closing one. Still keep it easy to ignore.

What should I copy and send?

Copy-ready template

Subject

Pharmaceuticals note on follow-up that ignores MLR, off-label risk,

Body

Hi [First Name],

If [pain] isn't a priority, you can delete this.

I'm writing because a label update, a launch window, or a congress. I don't need a demo. I can send a 6-line teardown of how [Company Name] might approach follow-up that ignores MLR, off-label risk, and the fact that 'just a quick claim' isn't quick.

Given this is long time no contact, ask if the old problem still exists, or if you should leave it archived.

Wrong person? Point me to whoever owns [pain].

Best,
[Your Name]
[Your Title]
[Your Company]

Questions people ask before they hit send

Yes, when they're specific. Generic sequences got crushed by filters and fatigue. Short emails that cite a real trigger and ask a real question still get replies. Volume without relevance just trains spam systems. Name the stall they care about, offer one small next step, and stop before the thread feels like a sequence.

Related templates

Want a custom draft instead? Try the email generator.